The major limitation was that there was no evaluation after the first cycle of camrelizumab treatment and before SBRT for this patient and that no PD-L1 expression was detected in the metastases; therefore, it was unclear whether the good response of the metastatic tumors was due to ICI treatment, SBRT, or their combination. Here, CD274 is linked to metastatic neoplasm.